Arm Holdings plc - American Depositary Shares (ARM)
325.54
+2.63 (0.82%)
NASDAQ · Last Trade: Sep 22nd, 9:56 AM EDT
Detailed Quote
Previous Close
322.90
Open
319.41
Bid
325.34
Ask
325.86
Day's Range
318.69 - 326.10
52 Week Range
100.02 - 452.70
Volume
992,719
Market Cap
-
PE Ratio (TTM)
434.05
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
4,580,108
Chart
About Arm Holdings plc - American Depositary Shares (ARM)
Arm Holdings plc is a leading technology company that specializes in semiconductor and software design, primarily focusing on microprocessor and system-on-chip (SoC) architectures. Its innovative designs are integral to a wide range of applications, from mobile devices to embedded systems and Internet of Things (IoT) products. Arm's technology enables low power consumption and efficient performance, making it a popular choice among manufacturers and developers in the electronics industry. The company collaborates closely with partners to drive the advancement of next-generation computing and connectivity solutions, playing a crucial role in shaping the future of digital devices and applications. Read More
Buyback announcements are cheap headlines. "$10 billion share repurchase program" sounds impressive regardless of whether the company can actually afford i
Sponsors rarely struggle to find advice. They struggle to find advice that holds up in front of an FDA review team, a slow-enrolling site network, and an i
Located along one of Gurugram’s established luxury residential corridors, Max Estate 59 is an upcoming residential development planned in Sector 59, close
Arm trades at a 125x forward P/E versus ASML's 27.9x, yet both command premium valuations for their monopolistic positions in mobile and chip manufacturing, respectively.
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX.
Zii
CytoDyn (OTCMKTS:CYDY) Chief Financial Officer Robert E. Hoffman outlined the company’s clinical-development plans for leronlimab, a CCR5-targeting humanized monoclonal antibody being studied in metastatic colorectal cancer, triple-negative breast cancer and other solid tumors.
Speaking at the Life
CHICAGO, IL - September 18, 2026 - Universal Wellness Roscoe Village continues to provide structured evaluation and care for patients seeking a neck pain chiropractor in Cook County, IL. The...
Astera Labs is riding explosive demand for AI connectivity chips with gross margins above 70%. Arm is compounding royalty revenue across billions of devices while its data center business accelerates.
Arm's licensing model generates 18.4% net margins with minimal debt, while Intel battles a net loss and negative free cash flow amid its foundry pivot.
GE Vernova is posting record orders and dramatically raising its free cash flow outlook. NextEra is executing steadily but navigating a major merger that won't close for another year.
